Cargando…

Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free

INTRODUCTION: Interferon (IFN)-free regimens for the treatment of chronic hepatitis C have shown high rates of sustained virological response (SVR) and improved patient-reported outcomes (PROs). The aim of this study was to evaluate the health-related quality of life (HRQoL) and fatigue of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fagundes, Raíssa Neves, Ferreira, Lincoln Eduardo Villela Vieira de Castro, Pace, Fábio Heleno de Lima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437906/ https://www.ncbi.nlm.nih.gov/pubmed/32813740 http://dx.doi.org/10.1371/journal.pone.0237005

Ejemplares similares

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

Miscellaneous Antiviral Agents (Interferons, Imiquimod, Pleconaril)
por: Dolin, Raphael
Publicado: (2015)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
por: Tavares, Rita Chelly Felix, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Interferons: Signaling, antiviral and viral evasion
por: Bonjardim, Cláudio A., et al.
Publicado: (2009)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals
por: Nagao, Yumiko, et al.
Publicado: (2016)

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha
por: da Silva, Andréa Marques Vieira, et al.
Publicado: (2021)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

Antiviral activities of interferons
por: Stewart, William E., et al.
Publicado: (1979)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy
por: Fatima, Tehreem, et al.
Publicado: (2020)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment
por: Vitiello, Glauco Akelinghton Freire, et al.
Publicado: (2021)

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders
por: Uemura, Haruka, et al.
Publicado: (2017)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
por: Pereira, Grenda Leite, et al.
Publicado: (2019)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Discovery of direct-acting antiviral agents with a graphene-based fluorescent nanosensor
por: Park, Se-Jin, et al.
Publicado: (2020)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
por: Sung, Pil Soo, et al.
Publicado: (2020)

Interferon-inducible antiviral effectors
por: Sadler, Anthony J., et al.
Publicado: (2008)

Antiviral defense: interferons and beyond
por: Stetson, Daniel B., et al.
Publicado: (2006)

Avian Interferons and Their Antiviral Effectors
por: Santhakumar, Diwakar, et al.
Publicado: (2017)

Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease
por: Chang, Christine Y., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ob0la6b0o3lpfngj72gha3e59